State-by-state rules: why peptide access is not the same everywhere

Think of it as two stacked rulebooks. The federal layer — the FDA's approval and compounding framework, and the DEA's control of scheduled drugs — defines what is broadly legal to make and sell. On top of that, each state regulates the practice of medicine and pharmacy within its borders through its own medical board and board of pharmacy. A peptide can be perfectly compliant federally and still be hard to obtain in a particular state because of how that state handles telehealth, out-of-state pharmacies, or who's allowed to prescribe. When access differs between two people, it's almost always this second layer doing the work.

Most peptide prescriptions today are written through telehealth, and telehealth is governed largely by state medical boards — which is where the variation concentrates ^[1]. States differ on whether a clinician needs a prior in-person examination before prescribing, whether an ongoing clinician-patient relationship is required, and how far "asynchronous" evaluation (a questionnaire reviewed without a live visit) can go. Some boards accept asynchronous models as long as the clinician has enough information for a reasonable judgment; others consider asynchronous prescribing of injectables, especially for off-label uses, below the standard of care. That disagreement is unresolved and genuinely state-specific, which is why an online clinic's footprint often looks like a patchwork map rather than "all fifty states."

The second big variable is the pharmacy. A compounding pharmacy that prepares your peptide generally must be licensed as a non-resident pharmacy in the state it ships to — holding your state's license, not just its own ^[2]. That single rule explains a lot of "why can't I get it here": the clinic may be fine, but its pharmacy isn't licensed in your state. On top of that, 503A compounding pharmacies are overseen jointly by the FDA and state boards of pharmacy, and the state standards vary — for example, whether "office stock" compounding (preparing ahead without a patient-specific prescription) is tolerated differs by state, even though the FDA's federal position is stricter ^[3]. So the same product can be routine in one state and unavailable in another purely because of where the pharmacy is licensed and how that state's board operates.

States also differ on scope of practice — which clinicians can prescribe and how independently. Physicians (MD/DO) can prescribe everywhere, but nurse practitioners and physician assistants operate under rules that range from full independent practice in some states to required physician supervision or collaborative agreements in others ^[4]. Because so much peptide prescribing runs through NP- and PA-staffed telehealth, a state's scope-of-practice rules can directly affect whether a given platform can serve you and under what supervision.

One area that trips people up: the strict federal telehealth limits on prescribing controlled substances (the framework tied to the Ryan Haight Act) generally do not apply to peptides, because most peptides are not DEA-scheduled controlled substances ^[5]. That's part of why peptide telehealth has been able to operate the way it does. The caveat is that a handful of substances can carry separate restrictions, and states can add their own controls beyond the federal list, so "not federally controlled" isn't a guarantee of "unrestricted in my state." It's one more thing to confirm rather than assume.

You don't need to read statutes to get a practical answer. Three moves cover most of it. First, ask the provider directly which states they're licensed to practice in and, crucially, which states their pharmacy ships to — a legitimate operation answers this plainly. Second, your state's board of pharmacy and board of medicine publish licensing and telehealth rules and can confirm whether a specific out-of-state pharmacy is licensed to ship in. Third, when a substance's federal compounding status is itself unsettled (as several peptides' currently is), state availability can shift with the federal decision, so check the timing too. If a source can't or won't tell you how it's licensed in your state, treat that as the answer.

State access isn't a fixed fact. Three things underneath it are all in motion: telehealth rules that many states revisited after the pandemic-era flexibilities lapsed, pharmacy licensing and enforcement priorities that shift with state budgets and board attention, and the federal compounding review that determines what's even eligible to prepare. A protocol that's easy to obtain in your state today can tighten — or loosen — within a year. That's not a reason for paralysis; it's a reason to verify current status rather than relying on what was true last year or what a forum says.